Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN9500-4656 NNC0194-0499 + semaglutide in NASH
2023-506961-74-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of nn9500, semaglutide and cagrilintide in metabolic dysfunction-associated steatohepatitis (MASH) (5 arms), sponsored by Novo Nordisk. Primary endpoint: Improvement in liver fibrosis and no worsening of NASH. Started May 2024; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-506961-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506961-74-00.